Beta Bionics, Inc. (BBNX) intrinsic value & 10-year financials
Beta Bionics, Inc. (BBNX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue grew 189.1% a year to $100.3M, with an average return on invested capital of 563.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $16.35
- Market cap
- $662.6M
- Revenue (FY2025)
- $100.3M
- Revenue growth (4-yr CAGR)
- 189.1%
- ROIC (10-yr avg)
- 563.9%
- Free cash flow (FY2025)
- -$56.2M
BBNX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $100.3M | -$73.2M | -$1.81 | -$56.2M | -71.5% | 1654.1% |
| FY2024 | $65.1M | -$54.8M | -$8.60 | -$51.7M | -69.5% | 18.2% |
| FY2023 | $12.0M | -$44.1M | -$8.31 | -$32.8M | -298.9% | 19.5% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Beta Bionics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Beta Bionics, Inc. has earned high returns on invested capital, averaging 18.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Beta Bionics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Beta Bionics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-60.12 per share.